On May 31st, Sanofi announced that its infant nasal spray respiratory syncytial virus attenuated live vaccine (RSVt vaccine, SP0125) has been approved by the Drug Evaluation Center of the National Medical Products Administration of China and can be used for clinical research. This is the first children's vaccine in China to participate in international multicenter clinical trials (MRCT) since the implementation of the new version of the Drug Registration Management Measures in 2020. Meanwhile, this vaccine is also the world's first infant and toddler vaccine designed to prevent diseases caused by respiratory syncytial virus (RSV), providing protection for infants and toddlers aged 6 to 24 months.